נועם דננברג – חדשות Wize Pharma
Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it amended the terms of certain convertible loans which had total outstanding amounts of approximately $1,520,000 that were due on November 30, 2019. Wize repaid approximately $760,000 of the total loan amount in cash, and the lenders have converted the remaining $760,000, thereby retiring the loans. As a result of the amendment, the conversion price was changed to $0.27 per share of common stock. Additionally, Wize has agreed to issue two warrants for each share of common stock issued to the lenders. The warrants have an exercise price of $0.27 per share and a term of 5 years.
“We are very pleased with our lenders having exercised part of their loans into equity expressing the faith in the company and facilitating the resources to continue our ongoing clinical program,” stated Wize’s CEO Noam Danenberg נועם דננברג. “We are eager to move forward with a clean balance sheet that has no remaining convertible loans.”
About Wize Pharma
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren’s syndrome (Sjögren’s).
LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and Sjögren’s and in the Netherlands for the treatment of DES and Sjögren’s. Wize’s strategy involves engaging local or multinational distributors to handle the distribution of LO2A. Wize has finished a Phase II trial of LO2A for patients with CCH and is currently conducting a Phase IV study for LO2A for DES in patients with Sjögren’s.
נועם דננברג יזם וניהל חברות הזנק משנות התשעים המוקדמות. בשנים האחרונות פעיל בתחום מדעי החיים ו- פודטק.
נועם דננברג סיים לימודי תואר ראשון במנהל עסקים והתמחות במחשבים ותואר שני אוניברסיטת בוסטון בבריסל במנהל עסקים והתמחות בייעוץ מס בינלאומי.